



ERG\NEO

L'AVENIR EST FAIT D'AUDACE



Paris, 01/03/2023

Press release

ERG\NEO

L'AVENIR EST FAIT D'AUDACE



An antibody enabling the development of new medical tests for the diagnosis of SARS-CoV-2 antibodies and other disease related to serological antibodies.

An exclusive license has been signed between Erganeo and Eldon Biologicals, a Danish company offering diagnostic tests based on red blood cell agglutination that are accessible to everyone. A quick and easy way to detect the presence of certain antibodies in the blood.

The Danish company, Eldon Biologicals, is known as the manufacturer of hospital kits and self-testing kits used in blood group determination. They can detect antibodies related to infectious diseases or to congenital abnormalities. They are simple, economical and provide a quick agglutination to be read with a naked-eye reading. They are also performed directly by users, requiring no medical appointment or laboratory equipment. The process used is based on the haemagglutination of red blood cells due to the presence of antigens on the surface of erythrocytes capable of reacting with specific antibodies. The efficiency of this type of test has been enhanced by advances in fusion proteins.

The company wishes to develop other devices for home use and for professional use. The first will be for the detection of immunisation against infectious agents such as the Covid 19 virus by diagnosing the presence of SARS-CoV-2 antibodies (Covid 19 immunisation). Other tests for diseases leaving antibodies in the blood will follow.

The most effective fusion protein for determining this immunisation is nanobody IH4. This "single-domain" IH4 or antibody (VHH) is derived from camelids and is easier to produce than human antibodies. It has the ability to target a red blood cell protein, Glycophorin A, more strongly and reliably than other antibodies against this red blood cell protein. This technology has been patented by Erganeo (INSERM, Université Paris Cité, Université des Antilles et de la Guyane), and Eldon Biologicals will be able to use it to develop these new diagnostics, thanks to the Exclusive License Agreement signed in September 2022, in the field of diagnostics.

"The use of this antibody will allow Eldon Biologicals to develop and market two new types of tests, which are expected to be launched in 2025 and in 2026," said Mr. Hedegaard, Director of Business Development of Eldon Biologicals.

"We are pleased to conclude this licensing agreement with Eldon Biologicals," said Naceur Tounekti, President of Erganeo. *"This transfer is in line with Erganeo's missions by allowing industrial partners to develop new products thanks to technologies from our territory's laboratories."*



ERG\NEO

L'AVENIR EST FAIT D'AUDACE



About Erganeo – www.erganeo.com

Erganeo is a French tech transfer company specialises in breakthrough innovations (deep tech) with a major societal impact. We invest early in the game to secure researchers' newest inventions before they are transferred to companies or before start-ups are founded, across a wide range of scientific fields: Biotech, Infotech (Telecom, connected objects, big data, AI) and Energetech (new energy, chemistry, materials), among others. Erganeo aims to accelerate and simplify links between research and industry for the benefit of society. To do so, we finance and accompany the new generation of French researchers and entrepreneurs on the road to international recognition and success.

As a member of the SATT Network, Erganeo draws on the Ile-de-France network in building the foundations of a better tomorrow, tapping into a talent pool of over 20,000 researchers across 350 cutting-edge, leading laboratories. Since it was founded, Erganeo has invested over €42m, thus contributing to the signing of 88 licensing agreements with companies of all sizes and setting up 31 start-ups.

Press contact: Caroline Pontifice - Communication and Marketing Manager - caroline.pontifice@erganeo.com

About Eldon Biologicals – <https://eldoncard.dk> www.eldoncard.com

Eldon Biologicals is the Danish manufacturer of EldonCards and EldonKits.

EldonCards were invented by the Danish physician Knud Eldon and are today sold world-wide.

EldonCards are used in the blood bank or in the laboratory, whereas EldonKits are used at point of care.

The shelf life of EldonCards and EldonKits is 24 months at temperatures up to 37 °C (99 °F), and the cards can be used on any location, even locations without electricity. These are qualities making EldonKits suitable for blood group determination at the bedside, in developing countries in the classroom and in warfare. It is expected that the new categories of EldonCards carrying fusion proteins will possess the same qualities.

Press contact: Hans-Ole Hedegaard - Int. 45 28833311 - hedegaard@eldoncard.com